APEIRON Expands Executive Board and Appoints
Dr. Anderson Gaweco as Chief Medical and Scientific Officer (CMSO)
APEIRON Biologics AG, a biotechnology company with a broad preclinical and clinical pipeline and an approved product on the market, focusing on the discovery and development of novel cancer immunotherapies, announced today the appointment of Anderson Gaweco, M.D., Ph.D. as its Chief Medical and Scientific Officer (CMSO).
(firmenpresse) - Vienna, Austria, 28 August 2018: APEIRON Biologics AG, a biotechnology company with a broad preclinical and clinical pipeline and an approved product on the market, focusing on the discovery and development of novel cancer immunotherapies, announced today the appointment of Anderson Gaweco, M.D., Ph.D. as its Chief Medical and Scientific Officer (CMSO).
Dr. Gaweco will lead APEIRONom discovery through commercialization both in the pharmaceutical and biotech industries.
Peter Llewellyn-Davies, President and CEO of APEIRON Biologics, said: &D pipeline of cutting-edge cancer immunotherapies, bring forward major near-term milestones of clinical-stage assets and support the expansion and transformative phase of APEIRON. His outreach into the worldwide pharmaceutical markets will support the long-term vision and strategy of APEIRON as a leader in cancer immunotherapies.
Dr. Manfred Reichl, Chairman of APEIRONf Penninger and the development successes of Dr. Hans Loibner. The APEIRON team, led by CEO Peter Llewellyn-Davies, will benefit significantly from his decades of scientific research and global drug development experience from early discovery through successful global product launches and commercial
Anderson Gaweco, M.D., Ph.D., designated CMSO of APEIRON Biologics added:
Dr. Gaweco joins APEIRON from Innovimmune Biotherapeutics, New York, as founder & CEO/CSO, where he led the discovery of novel immuno-oncology and autoimmune therapeutic programs. Previously, he was CMO at Lifecycle Pharma in Denmark/USA, held Global Clinical Leader positions at Roche and Pfizer, and was Senior Medical Scientist at AstraZeneca. Before joining the industry, Dr. Gaweco held dual faculty appointments as Assistant Professor of Medicine & Pathology at Loyola University Medical Center in Chicago. Dr. Gaweco worked on several NMEs leading to successful multi-billion dollar marketed pharmaceutical products: Xeljanz& Crestor
Dr. Gaweco received his M.D., Ph.D. in Immunology magna cum laude and obtained his residency in Pathology at the Ruprecht-Karls-Universittracts and several worldwide patents of NME immunotherapies in immuno-oncology and autoimmunity. He is currently Adjunct Professor at Georgetown University School of Medicine.
About APEIRON Biologics AG
Apeiron is a privately-held commercial-stage biopharmaceutical company based in Vienna, Austria, focused on the discovery, development and commercialization of novel cancer immunotherapies. The company is leveraging its innovative therapeutic targets based on tumor-specific targeted approaches and the stimulation of the immune system via novel and proprietary unique mechanisms of action (checkpoint blockade) to eradicate cancer by engaging the human body
For further information please contact:
APEIRON Biologics AG
Peter Llewellyn-Davies, CEO
Email: investors(at)apeiron-biologics.com
www.apeiron-biologics.com
Media Relations International
MC Services AG
Raimund Gabriel
T +49 89 210 228 0
Email: apeiron(at)mc-services.eu
Investor Relations
LifeSci Advisors, LLC
Chris Maggos
T +1 (646) 597 6989
Email: Chris(at)LifeSciAdvisors.com
Media Relations Austria:
PR&D - Public Relations for Research & Education
Till C. Jelitto, Ph.D., MBA
T +43 1 505 70 44
Email: jelitto(at)prd.at
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of APEIRON as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Increased awareness for Science & Research & Education. In Austria and around the world. That is our mission.
Datum: 29.08.2018 - 06:51 Uhr
Sprache: Deutsch
News-ID 1540310
Anzahl Zeichen: 2919
contact information:
Contact person: Till C. Jelitto
Town:
Vienna
Phone: +43 1 505 70 44
Kategorie:
Research & Development
Typ of Press Release: Unternehmensinformation
type of sending: Veröffentlichung
Date of sending: 29.08.2018
Anmerkungen:
Diese Pressemitteilung wurde bisher 974 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"APEIRON Expands Executive Board and Appoints Dr. Anderson Gaweco as Chief Medical and Scientific Officer (CMSO)
"
steht unter der journalistisch-redaktionellen Verantwortung von
PR&D - Public Relations for Research & Education (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
